BMY Jan 2026 67.500 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 12:19PM EDT. Market open.
| Previous close | 26.51 |
| Open | 26.51 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 67.50 |
| Expiry date | 2026-01-16 |
| Day's range | 26.51 - 26.51 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
ZacksBristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro
The FDA approves Bristol Myers' (BMY) cancer drug Augtyro for the treatment of adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
Business WireU.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
PRINCETON, N.J., June 13, 2024--U.S. FDA Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive....
ZacksBristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
© 2024 Yahoo. All rights reserved.